Luye Pharma Group Ltd (LUP) - Total Liabilities

Latest as of December 2025: €14.47 Billion EUR ≈ $16.91 Billion USD

Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has total liabilities worth €14.47 Billion EUR (≈ $16.91 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Luye Pharma Group Ltd (LUP) asset resilience to evaluate the company's liquid asset resilience ratio.

Luye Pharma Group Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how Luye Pharma Group Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Luye Pharma Group Ltd.

Luye Pharma Group Ltd Competitors by Total Liabilities

The table below lists competitors of Luye Pharma Group Ltd ranked by their total liabilities.

Company Country Total Liabilities
Jiangsu Jiangnan Water Co Ltd
SHG:601199
China CN¥2.60 Billion
ASGN Inc
NYSE:ASGN
USA $1.88 Billion
Guangzhou Guangri Stock Co Ltd
SHG:600894
China CN¥5.21 Billion
Zhejiang Goldensea Envi Tech C
SHG:603311
China CN¥427.35 Million
Dark Horse Beijing Technology Co Ltd
SHE:300688
China CN¥157.33 Million
Evergreen International Storage & Transport Corp
TW:2607
Taiwan NT$12.63 Billion
Apotea
ST:APOTEA
Sweden Skr1.26 Billion
Simply Good Foods Co
NASDAQ:SMPL
USA $644.32 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Luye Pharma Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Luye Pharma Group Ltd net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.53 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.90 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Luye Pharma Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Luye Pharma Group Ltd (2016–2025)

The table below shows the annual total liabilities of Luye Pharma Group Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 €14.47 Billion
≈ $16.91 Billion
+4.39%
2024-12-31 €13.86 Billion
≈ $16.20 Billion
+15.85%
2023-12-31 €11.96 Billion
≈ $13.99 Billion
-9.43%
2022-12-31 €13.21 Billion
≈ $15.44 Billion
-1.93%
2021-12-31 €13.47 Billion
≈ $15.75 Billion
+7.47%
2020-12-31 €12.53 Billion
≈ $14.65 Billion
+26.05%
2019-12-31 €9.94 Billion
≈ $11.62 Billion
+3.51%
2018-12-31 €9.60 Billion
≈ $11.23 Billion
+148.54%
2017-12-31 €3.86 Billion
≈ $4.52 Billion
+46.17%
2016-12-31 €2.64 Billion
≈ $3.09 Billion
--

About Luye Pharma Group Ltd

F:LUP Germany Drug Manufacturers - Specialty & Generic
Market Cap
$896.64 Million
€766.95 Million EUR
Market Cap Rank
#9438 Global
#1171 in Germany
Share Price
€0.19
Change (1 day)
+2.67%
52-Week Range
€0.19 - €0.39
All Time High
€0.70
About

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more